Understanding how genetic mutations affect social behavior in frontotemporal dementia.
Mechanisms of Thalamocortical Dysfunction and Social Deficits in FTD due to GRN Mutations
This study is looking at how changes in a gene called progranulin affect social skills in people with frontotemporal dementia, and it aims to find ways to improve these skills by boosting progranulin levels to help brain health.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project ID | NIH-10872277 on NIH RePORTER |
What this research studies
This research investigates the role of progranulin mutations in frontotemporal dementia (FTD) and how these mutations lead to social deficits. The study focuses on the mechanisms of thalamocortical dysfunction, which is crucial for social behavior, by examining the effects of progranulin on neuronal health and connectivity. Researchers will explore potential therapies that boost progranulin levels to restore its neuroprotective effects while minimizing risks. By using animal models, the research aims to uncover the underlying causes of social impairments associated with these genetic mutations.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with frontotemporal dementia linked to GRN mutations.
Not a fit: Patients with frontotemporal dementia not associated with GRN mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that improve social functioning in patients with frontotemporal dementia caused by GRN mutations.
How similar studies have performed: Previous research has shown promise in understanding the role of progranulin in neurodegenerative diseases, indicating potential for success in this area.
Where this research is happening
Birmingham, United States
- University of Alabama at Birmingham — Birmingham, United States (Active)
Researchers
- Principal investigator: Arrant, Andrew Emmett — University of Alabama at Birmingham
- Study coordinator: Arrant, Andrew Emmett
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.